# Judge — L4-TICK7-REDEFINE — iter1

**Judge:** Agent J (Kimi K3). Did NOT write this increment. Mood: critic.
**Date judged:** 2026-09-02. **Loop:** L4 (Integrity — false facts). **Verdict: KEEP.**

Increment diff (git, working copy vs HEAD): 2 files, +55/−55. Both files are
tracked, pre-existing slugs — modified, not created.

## Independent re-fetches (this run, by Judge)

1. `efetch pubmed id=40544432` (REDEFINE 2, NEJM 2025;393(7):648-659) — fetched 2026-09-02.
2. `efetch pubmed id=40544433` (REDEFINE 1, NEJM 2025;393(7):635-647) — fetched 2026-09-02 (mixup check).
3. `clinicaltrials.gov/api/v2/studies/NCT06131437` — fetched 2026-09-02.
4. `esearch "REDEFINE 4" + cagrilintide + tirzepatide` → `count: 0` — fetched 2026-09-02.
5. Grep both MDX for `22.7 | 15.7 | 40.4 | 25.5 | 14.9 | 11.5 | 23% | 28.7 | 63%` → **0 matches in either file.**

## Per-criterion findings

| # | Criterion | Result | Evidence |
|---|---|---|---|
| 1 | REDEFINE 2 numbers match fetched abstract (PMID 40544432) | PASS | `cagrisema-nda-filed.mdx` quotes −13.7% vs −3.4%, ETD −10.4 pp (95% CI −11.2 to −9.5; P<0.001), HbA1c ≤6.5% 73.5% vs 15.9%, GI 72.5% vs 34.4%, n=1206 (904/302), 68 wk, treatment-policy. Fetched abstract matches every figure verbatim. Abstract states treatment-policy estimand; page leads with it. |
| 2 | Trial-product −15.7% stripped | PASS | Diff removes the "trial-product estimand −15.7% / −3.1%" table row; grep clean; page states the abstract does not report a trial-product percent. Fetched abstract confirms it does not. |
| 3 | REDEFINE 1 numbers correct sibling (PMID 40544433, no mixup) | PASS | Page attaches −20.4%/−3.0%, ETD −17.3 pp (−18.1 to −16.6), GI 79.6%/39.9%, 21:3:3:7, n=3417 (2108/302/302/705) to `redefine-trials-overview`/`redefine-1-results` = 40544433. Fetched 40544433 abstract matches all. No REDEFINE-2 figure cited to 40544433 or vice versa. GI sentence re-cited correctly per-trial in the diff. |
| 4 | Stripped figures gone (22.7, 40.4, −14.9, −11.5) | PASS | Grep clean both files. Diff removes trial-product 22.7%/40.4% sentence and the monotherapy percent list. Fetched 40544433 abstract confirms it does not publish monotherapy percents or threshold percents — page now says exactly that instead of inventing them. |
| 5 | REDEFINE 4: 23%/25.5% not quoted; registry-only, dated absence | PASS | Grep clean. Both files now describe NCT06131437 from the registry only. Fetched CT.gov record matches page claims exactly: COMPLETED, masking NONE (open-label), enrollment 809 ACTUAL, phase 3, primary = non-inferiority on relative body-weight change at week 84, primary completion 2025-12-08, completion 2026-01-09, last update posted 2026-02-06, `hasResults: false`. Absence claims carry "as of 2026-09-02" window dates, confirmed by my own esearch (0 hits). |
| 6 | No new URLs | PASS | `git status`: both files `M`, not `??`. No new slug. One added internal link (`/compare/cagrilintide-vs-survodutide`) — verified the target file exists, along with all 7 other linked slugs (cagrisema, cagrilintide, semaglutide, tirzepatide, orforglipron, retatrutide, cagrisema-vs-tirzepatide). |
| 7 | No banned content; no titration schedule | PASS | Diff deletes the "Titration: 4-week dose escalation schedule" label-preview block and replaces it with "This page does not preview a titration schedule or a milligram dose." The 2.4 mg/2.4 mg mention describes the studied formulation, not dosing advice. No purchasing/sourcing language. |
| 8 | OSA 63% / TRIUMPH 28.7% not restored | PASS | Grep for `63%` and `28.7`: 0 matches in both files. |
| 9 | Citation-id hygiene | PASS | File 1: 5 sources YAML ids, all cited in body, all body cites resolve. File 2: 8 ids, all resolve. Both identifiers introduced this run (`pmid-40544432`, `nct-06131437`) were re-fetched and topical-matched by me this run. No auto-attach. No journal-homepage "sources." |
| 10 | Estimand leadership + escaping | PASS | Treatment-policy (published primary) leads for REDEFINE 1/2 per both abstracts. REIMAGINE section (untouched by this diff) keeps efficacy-estimand labelling. `P<0.001` escaped as `P&lt;0.001` in MDX. |

## Gaming check

The implementer stripped more than the fail list strictly required — monotherapy percents, a retatrutide-from-memory figure, pricing speculation, and patient-selection bullets all went. Overstripping has a real cost: the monotherapy percents (−14.9%/−11.5%) are genuinely in the NEJM full text, so the page is now thinner than the published record, and two qualitative remnants ("the combination outperforms either peptide alone… falling short of a simple additive effect") assert a comparison whose numeric basis the same page declines to quote — directionally correct per the full paper, but not derivable from the fetched abstract. That is a nitpick, not a violation: the claim is qualitative, cited to the right PMID, and the fail list targets figures, not hedged prose. No SEO gaming: no new URL, no link dump, no sitemap play, lastUpdated bumped honestly. The implementer did not self-certify; LOOP-TASKS labels were not used as evidence — every number above was re-derived from my own fetches of PubMed/CT.gov and a fresh grep, not from TICK7-REDEFINE.md.

## Verdict

**KEEP.** All ten criteria pass on independently fetched evidence. Every task-specific fail condition checked negative: no invented figure, no 23%/25.5%, no live −15.7%, no new slug, no OSA/TRIUMPH restoration, no sibling mixup.

**Non-blocking observation for a future pass:** if the conductor wants the monotherapy percents or the REDEFINE 4 topline back on the page, they need a fetched full-text/press source first (GlobeNewswire timed out for the implementer; retry or use the Novo press release directly). Until then, absence-with-date is the correct posture.
